Episode Details
Back to Episodes
Skyclarys Approved for Friedreich's Ataxia | Belfast News
Description
Friedreich’s Ataxia patients get a major breakthrough: the HSE will now cover Skyclarys, a drug that slows nerve damage—though it doesn’t cure the disease. After a two-year battle, Biogen slashed its initial €288,000 annual price following HSE negotiations, with final figures kept secret for commercial reasons. The approval process, designed for industry insiders, left patients waiting anxiously outside clinics, highlighting how opaque and inaccessible the system remains—even as it saves lives.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/eec3a60592f026b7